-
Mashup Score: 8Annual Meeting Abstracts - 1 day(s) ago
Submit your abstract to ACR Convergence. See submission & presentation guidelines. Also see permission & reprint policies & abstract embargo policy.
Source: rheumatology.orgCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 8Annual Meeting Abstracts - 13 day(s) ago
Submit your abstract to ACR Convergence. See submission & presentation guidelines. Also see permission & reprint policies & abstract embargo policy.
Source: rheumatology.orgCategories: General Medicine News, RheumatologyTweet-
The time is now to make your plans for #ACR24 in Washington, D.C., Nov. 14-19. Plus, the call for abstracts opens NEXT WEEK on Tuesday, April 23! Details → https://t.co/446NriZwim https://t.co/x6Zg8sp8Zg
-
-
Mashup Score: 8Annual Meeting Abstracts - 16 day(s) ago
Submit your abstract to ACR Convergence. See submission & presentation guidelines. Also see permission & reprint policies & abstract embargo policy.
Source: rheumatology.orgCategories: General Medicine News, RheumatologyTweet-
The time is now to make your plans for #ACR24 in Washington, D.C., Nov. 14-19. Plus, the call for abstracts opens NEXT WEEK on Tuesday, April 23! Details → https://t.co/446NriZwim https://t.co/x6Zg8sp8Zg
-
-
Mashup Score: 8Annual Meeting Abstracts - 28 day(s) ago
Submit your abstract to ACR Convergence. See submission & presentation guidelines. Also see permission & reprint policies & abstract embargo policy.
Source: rheumatology.orgCategories: General Medicine News, RheumatologyTweet-
The time is now to make your plans for #ACR24 in Washington, D.C., Nov. 14-19. Plus, the call for abstracts opens NEXT WEEK on Tuesday, April 23! Details → https://t.co/446NriZwim https://t.co/x6Zg8sp8Zg
-
-
Mashup Score: 8Annual Meeting Abstracts - 2 month(s) ago
Submit your abstract to ACR Convergence. See submission & presentation guidelines. Also see permission & reprint policies & abstract embargo policy.
Source: rheumatology.orgCategories: General Medicine News, RheumatologyTweet-
The time is now to make your plans for #ACR24 in Washington, D.C., Nov. 14-19. Plus, the call for abstracts opens NEXT WEEK on Tuesday, April 23! Details → https://t.co/446NriZwim https://t.co/x6Zg8sp8Zg
-
-
Mashup Score: 74
Background/Purpose: Interstitial lung disease (ILD) is a serious extra-articular manifestation of RA, affecting 7-12% of patients and associated with three-fold increased mortality compared to RA without ILD. The associations between the use of DMARDs and the development of ILD among patients with RA remain unclear. Thus, we conducted a systematic literature review for studies investigating DMARDs […]
Source: acrabstracts.orgCategories: General Medicine News, General HCPsTweet-
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w5G1dEF7Vm https://t.co/cyiQqGBf01 https://t.co/r909qqIh4V
-
-
Mashup Score: 80
Background/Purpose: Interstitial lung disease (ILD) is a serious extra-articular manifestation of RA, affecting 7-12% of patients and associated with three-fold increased mortality compared to RA without ILD. The associations between the use of DMARDs and the development of ILD among patients with RA remain unclear. Thus, we conducted a systematic literature review for studies investigating DMARDs […]
Source: acrabstracts.orgCategories: General Medicine News, General HCPsTweet-
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2
-
-
Mashup Score: 56
Background/Purpose: The objective was to assess the efficacy and safety of UPA vs placebo (PBO), in combination with a GC taper regimen, in patients with GCA. Methods: SELECT-GCA is a double-blind, randomized PBO-controlled phase 3 trial conducted in 24 countries, consisting of two 52-week periods. Results from the first 52-week period (primary analysis) are reported […]
Source: acrabstracts.orgCategories: General Medicine News, RheumatologyTweet-
Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/f7OwxAggaf… https://t.co/PUuwo0MLso https://t.co/JBzokT9icx
-
-
Mashup Score: 102Frequency and Clinical Utility of Antibodies to Extractable Nuclear Antigen in the Setting of a Negative Antinuclear Antibody Test - PubMed - 4 month(s) ago
Despite the higher-than-expected incidence of positive ENA in the setting of a negative ANA, the yield of newly diagnosed rheumatic diseases was low. Our findings support the stepwise addition of ENA requests when an ANA test result is positive and clinical suspicion of an AARD is high.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, General HCPsTweet-
ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/7Lo0DgHtXT) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow… https://t.co/lZ1TJxTqhs https://t.co/itx0TCFFjl
-
-
Mashup Score: 2Log In - 5 month(s) ago
Log in to the American College of Rheumatology (ACR) website.
Source: my.rheumatology.orgCategories: General Medicine News, RheumatologyTweet-
If you're attending #ACR24, join us for this session hosted in partnership with the @oaactionallianc and @CDCgov. Add it to your ACR agenda: https://t.co/4sD73mzZMC https://t.co/hJkh3gRcNm
-
The time is now to make your plans for #ACR24 in Washington, D.C., Nov. 14-19. Plus, the call for abstracts opens NEXT WEEK on Tuesday, April 23! Details → https://t.co/446NriZwim https://t.co/x6Zg8sp8Zg